

October 23, 2024



# TuHURA Biosciences (Nasdaq: HURA) Announces Webcast Replay of Panel Presentation at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC

**TAMPA, FL / ACCESSWIRE / October 23, 2024** / TuHURA Biosciences, Inc. (Nasdaq:HURA) ("TuHURA" or the "Company"), a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced that TuHURA recently participated at the [2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC](#).



As part of the event, [Dr. James Bianco, President and Chief Executive Officer of TuHURA](#) participated in the [Precision and Immune Oncology](#) panel. To access the webcast replay, sign up to become an [M-Vest member](#).

## **About TuHURA Biosciences, Inc.**

TuHURA Biosciences, Inc. is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma.

In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.

For more information, please visit [tuhurabio.com](http://tuhurabio.com) and connect with TuHURA on [Facebook](#), [X](#), and [LinkedIn](#).

**Investor Contact:**

Jenene Thomas

JTC Team, LLC

908.824.0775

[tuhura@jtcir.com](mailto:tuhura@jtcir.com)

**SOURCE:** TuHURA Biosciences, Inc.

View the original [press release](#) on [accesswire.com](http://accesswire.com)